

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2922483

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	DONALD JEFFREY KEYSER	02/25/2014
	ALVARO F. GUILLEM	02/26/2014
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	ZS PHARMA, INC.	
<b>Street Address:</b>	508 WRANGLER DRIVE	
<b>City:</b>	COPPELL	
<b>State/Country:</b>	TEXAS	
<b>Postal Code:</b>	75019	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	14321634
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(202)778-2201	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	202-955-1500	
<b>Email:</b>	ccurrie@hunton.com	
<b>Correspondent Name:</b>	HUNTON & WILLIAMS LLP	
<b>Address Line 1:</b>	2200 PENNSYLVANIA AVENUE, N.W.	
<b>Address Line 2:</b>	INTELLECTUAL PROPERTY DEPARTMENT	
<b>Address Line 4:</b>	WASHINGTON, D.C. 20037-1701	
<b>ATTORNEY DOCKET NUMBER:</b>	76955.000064	
<b>NAME OF SUBMITTER:</b>	ROBERT M. SCHULMAN	
<b>SIGNATURE:</b>	/31196/	
<b>DATE SIGNED:</b>	07/01/2014	
<b>Total Attachments: 3</b>		
source=5Assn64#page1.tif		
source=5Assn64#page2.tif		
source=5Assn64#page3.tif		

## ASSIGNMENT

WHEREAS, WE, **Donald Jeffrey KEYSER** residing at **1216 Wyndham Hill Lane, Southlake, TX 76092**; and **Alvaro F. GUILLEM** residing at **727 Lathrop Street, Lantana, TX 76226** (hereinafter "ASSIGNORS"); have invented certain new and useful improvements in and to the subject matter of:

### MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA

described in a United States Provisional Application filed on **February 11, 2011** and accorded Provisional Application No. **61/441,893**; and United States Applications accorded Application Nos. **13/371,080** filed on **February 10, 2012**; **14/036,489** filed on **September 25, 2013**; **14/096,692** filed **December 4, 2013**; **14/096,712** filed **December 4, 2013**; and **14/096,728** filed **December 4, 2013**;

AND, WHEREAS, **ZS Pharma, Inc.**, a corporation organized under the laws of Delaware, having a place of business located at **508 Wrangler Drive, Coppell, Texas, 75019** (hereinafter "ASSIGNEE"), has acquired certain rights to the improvements and under the applications;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) or the equivalent thereof, and other good and valuable consideration, receipt of which is hereby acknowledged, WE do hereby acknowledge and confirm that WE have previously sold, assigned, and transferred, pursuant to certain prior agreements between the ASSIGNORS and ASSIGNEE, unto said ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and throughout the United States of America (including its territories and dependencies) and all countries foreign thereto in and to said improvements, said United States application, any other United States applications, including provisional, divisional, renewal, substitute, continuation, reexamination and reissue applications, based in whole or in part on said United States application or in whole or in part on said improvements, any foreign applications, including international and regional applications, based in whole or in part on any of the aforesaid United States applications or in whole or in part on said improvements, and in and to any and all letters patent, including extensions thereof, of any country which have been or may be granted on any of the aforesaid applications or on said improvements or any parts thereof; and WE do hereby acknowledge and confirm that all such rights have always been owned by ASSIGNEE from the time said improvements were invented.

AND WE hereby authorize and request our agents, **Hunton & Williams LLP**, whose address is **2200 Pennsylvania Avenue, N.W., Washington, DC 20037**, to insert hereon any identification necessary or desirable for recordation of this document, including the filing date and application number of said application when known.

AND WE hereby agree for ourselves and our heirs, executors and administrators to execute without further consideration any further documents and instruments which may be

reissue application or in any amendments, extensions or interference proceedings, or other applications for patents of any region or country, that may be necessary to secure to ASSIGNEE its interest and title in and to said improvements or any parts thereof, and in and to said several patents or any of them;

AND WE hereby covenant for ourselves and our legal representatives, and agree with said ASSIGNEE, its successors and assigns, that WE have granted no right or license to make, use, sell or offer to sell said improvements, to anyone except said ASSIGNEE, and that WE have not and will not execute any instrument in conflict therewith;

AND WE do hereby authorize and request the Director of the United States Patent and Trademark Office to issue any and all letters patent which may be granted upon said United States applications, or upon said improvements or any parts thereof when granted, to said ASSIGNEE.

IN WITNESS WHEREOF, I have hereunto set my hand and seal.

02/25/2014  
Date

Donald Jeffrey Keyser  
Donald Jeffrey KEYSER

Witnessed hereto:

Vanessa Hendrickson  
Signature

Vanessa Hendrickson  
Print Name


2-25-14  
Date


HUNTON & WILLIAMS LLP  
INTELLECTUAL PROPERTY DEPARTMENT  
2200 PENNSYLVANIA AVENUE, N.W.  
WASHINGTON, DC 20037  
(202) 955-1500 (TELEPHONE)  
(202) 778-2201 (FACSIMILE)

2<sup>16</sup>3/26/14  
Date

  
Alvaro F. GUILLEM

Witnessed hereto:

  
Signature

  
Print Name

2-26-14  
Date

HUNTON & WILLIAMS LLP  
INTELLECTUAL PROPERTY DEPARTMENT  
2200 PENNSYLVANIA AVENUE, N.W.  
WASHINGTON, DC 20037  
(202) 955-1500 (TELEPHONE)  
(202) 778-2281 (FACSIMILE)